marked.bio

Company

Tyra Biosciences

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

TYRA-300 2

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Recruiting Phase 2 Tyra Biosciences Started 2025Primary completion 2028-02 NCT06995677

    TYRA-300

    Documented activating FGFR3 alteration (mutation or fusion)

    FGFR3 alteration (mutation or fusion)Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration

  2. Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

    Active, not recruiting Phase 1/2 Tyra Biosciences Started 2022Primary completion 2026-11 NCT05544552

    TYRA-300

    Histologically confirmed advanced solid tumor with an eligible FGFR3 gene mutation or fusion (Part B).

    FGFR3 alteration (mutation or fusion)Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

  3. Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

    Active, not recruiting Phase 1 Tyra Biosciences Started 2023Primary completion 2027-03 NCT06160752

    Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyPhase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyc

    …histologically confirmed advanced solid tumor with FGFR/FGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have ex…

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementLocally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma